Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-11-21
2011-10-11
Vivlemore, Tracy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A
Reexamination Certificate
active
08034921
ABSTRACT:
The invention relates to iRNA agents that preferably include a modification that targets CC chemokine receptor 5 (CCR5). The invention also relates to methods of making and using such modified iRNA agents.
REFERENCES:
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0170618 (2004-09-01), Davis et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0256069 (2005-11-01), Manoharan et al.
patent: 2006/0094678 (2006-05-01), Vornlocher et al.
patent: 2007/0004664 (2007-01-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 1448515 (2004-08-01), None
patent: WO 02/22599 (2002-03-01), None
patent: WO 2005/115481 (2005-12-01), None
Burrows et al. Bioorganic and Medicinal Chemistry Letters 2005, vol. 15, pp. 25-28.
Agrawal, S., et al., “Antisense oligonucleotides: towards clinical trials.” Trends in Biotechnology. Oct. 1996, vol. 14, pp. 376-387.
Bass, B., “The short answer,” Nature, May 24, 2001, pp. 428-429, vol. 411.
Elbashir, S., et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,” Methods, 2002, pp. 199-213, vol. 26.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S., et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate,” The EMBO Journal, 2001, pp. 6877-6888, vol. 20, No. 23.
Elbashir, S., et al., “RNA Interference is Mediated by 21-and 22 Nucleotide RNAs,” Genes & Development, 2001, pp. 188-200, vol. 15.
Fire, A., “RNA-triggered Gene Silencing,” Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.
Fire, A., et al., “Potent and Specific Genetic Interference by Double Stranded RNA in Caenorhabditis elegans,” Nature, Feb. 19, 1998, pp. 806-811, vol. 391.
Tuschl, T., “Functional genomics: RNA sets the standard,” Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.
Tuschl T., “RNA Interference and Small Interfering RNAs” Chembiochem, 2001, pp. 239-245, vol. 2.
Tuschl, T., et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.
Tuschl, T., “Mammalian RNA Interference,” RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.
Tuschl, T., et al., “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,” Genes & Development, 1999, pp. 3191-3197, vol. 13.
Tuschl, T., “Expanding small RNA interference,” Nature Biotechnology, May 2002, pp. 446-448, vol. 20.
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
Burrows, J., et al., Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(-3,3-diphenylpropyl)-piperidinyl amides and ureas, Bioorg. Med. Chem. Lett. 2005, pp. 25-28, vol. 15.
Hammond, S.M., et al., “Argonaute2, a link between genetic and biochemical analyses of RNAi,” Science, Aug. 10, 2001, pp. 1146-1150, vol. 293, No. 5532.
Imamura, S., et al., “CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives,” Bioorg. Med. Chem. Lett. 13:397-416, 2005.
Imamura, S., et al., “CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N0-diphenylureas,” Bioorg. Med. Chem. 12:2295-2306, 2004.
Kazmierski, W., et al., “Recent progress in discovery of small-molecule CCR5 chemokine receptor ligsnds as HIV-1 inhibitors,” Bioorg Med Chem, 2003, 11: 2663-2676.
Ketting, R., el al. “Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing inC. elegans,” Genes & Development, Oct. 15, 2001, pp. 2654-2659, vol. 15, No. 20.
Limbach, P., et al., “Summary: the modified nucleosides of RNA,” Nucleic Acids Res., 1994, pp. 2183-2196, vol. 22, No. 12.
Maeda, K., et al., Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro, J. Virol., 2004, vol. 78, pp. 8654-8662.
Marozsan, A., et al., “Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D),” Virology, Jul. 20, 2005, pp. 182-199, vol. 338, No. 1.
Ribeiro, S., et al., “The clinical potential of chemokine receptor antagonists,” Pharmacology and Therapeutics, Jul. 2005, pp. 44-58, vol. 107, Issue 1.
Seto, M., et al., “Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activity of 1-Benzothiepine 1, 1-Dioxide and 1-Benzazepine Derivatives Containing a Tertiary Amine Moiety,” Chem. Pharm. Bull. 52:577-590, 2004.
Thoma, G., et al., “Orally Bioavailable Competitive CCR5 Antagonists,” J. Med. Chem. 47:1939-1955, 2004.
Veazey, R.S., et al., “Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120,” Nature Medicine, 2003, pp. 343-346, vol. 9.
NM—000579 (GenBank [online] Bethesda, MC USA: United States National Library of Medicine [version dated Nov. 17, 2006; retrieved on Feb. 1, 2009] Retrieved from the internet URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?4502638:NCBI:15626606>, GenBank Accession No. NM—000579), 5 pages.
NM—000579 for CCR5 mRNA (GenBank [online] Bethesda, MC USA: United States National Library of Medicine [version dated Sep. 23, 2005; retrieved on Sep. 27, 2005] Retrieved from the internet URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=4502638>, GenBank Accession No. NM—000579), 28 pages.
Manoharan Muthiah
Rajeev Kallanthottahil G.
Alnylam Pharmaceuticals, Inc.
Fenwick & West LLP
Vivlemore Tracy
LandOfFree
IRNA agents targeting CCR5 expressing cells and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IRNA agents targeting CCR5 expressing cells and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IRNA agents targeting CCR5 expressing cells and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4269460